Sio Gene up on FDA fast track tag for rare disease drug

Sio Gene Therapies

01/11/2021 13:08

** Sio Gene Therapies Inc's shares  SIOX.O  up 2.6% at $1.94
in premarket trade
    ** Says U.S. FDA has granted "fast track" designation to its
investigational gene therapy, AXO-AAV-GM2, for treatment of
Tay-Sachs and Sandhoff diseases, both rare and fatal pediatric
diseases with no approved treatments  urn:newsml:reuters.com:*:nGNX8n8zhZ
    ** Fast track designation is a process designed to expedite
FDA review of drugs to treat serious conditions and fill an
unmet medical need
    ** The investigational gene therapy is currently in
early-to-mid stage study to determine safety and efficacy of
gene therapy
    ** Last week, FDA granted the fast track status to co's
AXO-AAV-GM1, a potential treatment for another rare pediatric
disease, GM1 gangliosidosis  urn:newsml:reuters.com:*:nNRAh4snng
    ** Up to Friday's close, stock had fallen 31.3% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com;))